-
U.S. Tax Credits to Promote Practical Proactive Preventative Care for Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-03-05 Michael S. Okun
Abstract Persons with Parkinson’s disease (PD) and society at large can profit from a strategic investment into a forward leaning, practical, preventative, and proactive multidisciplinary care policy. The American healthcare system is not easily bent to accommodate this type of care, and thus a tax benefit is an attractive option. An individual federal income tax benefit of $6200 each year for every
-
Do Bacterial Outer Membrane Vesicles Contribute to Chronic Inflammation in Parkinson’s Disease? J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-03-05 Tiana F. Koukoulis, Leah C. Beauchamp, Maria Kaparakis-Liaskos, Rachel M. McQuade, Adityas Purnianto, David I. Finkelstein, Kevin J. Barnham, Laura J. Vella
Abstract Parkinson’s disease (PD) is an increasingly common neurodegenerative disease. It has been suggested that the etiology of idiopathic PD is complex and multifactorial involving environmental contributions, such as viral or bacterial infections and microbial dysbiosis, in genetically predisposed individuals. With advances in our understanding of the gut-brain axis, there is increasing evidence
-
Metabotropic Glutamate Receptor 4 (mGlu 4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-03-05 Clare J. Finlay, Michael J. Jackson, Ria Fisher, Christoffer Bundgaard, Sarah Rose, Susan Duty
Abstract Background: Increased activity across corticostriatal glutamatergic synapses may contribute to L-DOPA-induced dyskinesia in Parkinson’s disease. Given the weak efficacy and side-effect profile of amantadine, alternative strategies to reduce glutamate transmission are being investigated. Metabotropic glutamate receptor 4 (mGlu4) is a promising target since its activation would reduce glutamate
-
Striatal Serotonin 4 Receptor is Increased in Experimental Parkinsonism and Dyskinesia J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-03-05 Rossella Cirillo, Sandra Duperrier, Pathik Parekh, Mathilde Millot, Qin Li, Marie-Laure Thiolat, Micaela Morelli, Jing Xie, Didier Le Bars, Jérôme Redouté, Erwan Bezard, Véronique Sgambato
Abstract Alterations of serotonin type 4 receptor levels are linked to mood disorders and cognitive deficits in several conditions. However, few studies have investigated 5-HT4R alterations in movement disorders. We wondered whether striatal 5-HT4R expression is altered in experimental parkinsonism. We used a brain bank tissue from a rat and a macaque model of Parkinson’s disease (PD). We then investigated
-
Kinematic Effects of Combined Subthalamic and Dorsolateral Nigral Deep Brain Stimulation in Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-03-05 Daniel Kroneberg, Bassam Al-Fatly, Cornelia Morkos, Leon Amadeus Steiner, Gerd-Helge Schneider, A. Kühn
Abstract Background: Additional stimulation of the substantia nigra (SNr) has been proposed to target axial symptoms and gait impairment in patients with Parkinson’s disease (PD). Objective: This study aimed to characterize effects of combined deep brain stimulation (DBS) of the subthalamic nucleus (STN) and SNr on gait performance in PD and to map stimulation sites within the SNr. Methods: In a double-blinded
-
Neural Oscillations and Functional Significances for Prioritizing Dual-Task Walking in Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-03-05 Cheng-Ya Huang, Yu-An Chen, Ruey-Meei Wu, Ing-Shiou Hwang
Abstract Background: Task prioritization involves allocating brain resources in a dual-task scenario, but the mechanistic details of how prioritization strategies affect dual-task walking performance for Parkinson’s disease (PD) are little understood. Objective: We investigated the performance benefits and corresponding neural signatures for people with PD during dual-task walking, using gait-prioritization
-
DRD3 Predicts Cognitive Impairment and Anxiety in Parkinson’s Disease: Susceptibility and Protective Effects J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-03-05 Alexandra Gonçalves, Alexandre Mendes, Joana Damásio, Nuno Vila-Chã, Daniela Boleixa, Bárbara Leal, Sara Cavaco
Abstract Background: A possible genetic contribution of dopamine D3 receptor (DRD3) to cognitive impairment in Parkinson’s disease (PD) has yet to be investigated. Objective: To explore the effects of rs6280 (Ser9Gly) genotype on PD patients’ cognitive performance and to clarify possible interactions with psychopathology. Methods: Two hundred and fifty-three consecutive PD patients underwent neurological
-
The Degree of Cardiovascular Autonomic Dysfunction is not Different in GBA-Related and Idiopathic Parkinson’s Disease Patients: A Case-Control Instrumental Evaluation J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-03-05 Giulia Giannini, Raffaella Minardi, Giorgio Barletta, Ilaria Cani, Annagrazia Cecere, Luca Baldelli, Alessia Fiorentino, Pietro Guaraldi, Luisa Sambati, Sabina Capellari, Pietro Cortelli, Valerio Carelli, Giovanna Calandra-Buonaura
Abstract Background: Increased prevalence of cardiovascular autonomic failure might play a key role on Parkinson’s disease (PD) progression of glucocerebrosidase gene (GBA)-mutated patients, determining a malignant phenotype of disease in these patients. Objective: To objectively characterize, for the first time, the cardiovascular autonomic profile of GBA-mutated patients compared to idiopathic PD
-
Alleviating Stress in Parkinson’s Disease: Symptomatic Treatment, Disease Modification, or Both? J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-02-15 Franziska Goltz, Anouk van der Heide, Rick C. Helmich
Abstract Psychological stress, a state of mental strain caused by mentally or physically threatening situations, plays a significant role in Parkinson’s disease (PD). Motor symptoms worsen during acute stress and common non-motor symptoms in PD, such as anxiety and depression, are linked to chronic stress. Although evidence in humans is lacking, animal models of PD suggest that chronic stress can accelerate
-
Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-02-03 Hendrik Theis, Nicola Pavese, Irena Rektorová, Thilo van Eimeren
Abstract Assessing imaging biomarker in the prodromal and early phases of Parkinson’s disease (PD) is of great importance to ensure an early and safe diagnosis. In the last decades, imaging modalities advanced and are now able to assess many different aspects of neurodegeneration in PD. MRI sequences can measure iron content or neuromelanin. Apart from SPECT imaging with Ioflupane, more specific PET
-
Cost-Effectiveness Analyses of Non-Pharmacological and Non-Surgical Interventions in Idiopathic Parkinson’s Disease: A Systematic Review J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-02-03 Daniel Hartmann-Nardin, Stephanie Stock, Elke Kalbe, Ann-Kristin Folkerts
Abstract Background: Interest in non-pharmacological/non-surgical interventions to treat Parkinson’s disease (PD) has substantially increased. Although a few health-economic studies have been conducted, summary information on the cost-effectiveness is still scarce. Objective: To give an overview of cost-effectiveness analyses (CEA) focusing on non-pharmacological/non-surgical interventions in PD patients
-
Dietary Interventions in Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-01-23 Indy van der Berg, Sabine Schootemeijer, Karin Overbeek, Bastiaan R. Bloem, Nienke M. de Vries
Abstract Several dietary patterns and nutritional supplements have been linked to the development, progression, and symptomatic treatment of Parkinson’s disease (PD). Most of the evidence, at this point, is preliminary and based largely on observational studies. Interventional studies are scarce, so the evidence on effectiveness remains inconclusive. Dietary interventions could, analogous to exercise
-
Defining a Lewy Body: Running Up the Hill of Shifting Definitions and Evolving Concepts J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-01-23 Tim E. Moors, Dragomir Milovanovic
Abstract Lewy bodies (LBs) are pathological hallmarks of Parkinson’s disease and dementia with Lewy bodies, characterized by the accumulation of α-synuclein (αSyn) protein in the brain. While LBs were first described a century ago, their formation and morphogenesis mechanisms remain incompletely understood. Here, we present a historical overview of LB definitions and highlight the importance of semantic
-
Addressing Comorbidities in People with Parkinson’s Disease: Considerations From An Expert Panel J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-01-23 Camille Carroll, Carl E. Clarke, Donald Grosset, Arshad Rather, Biju Mohamed, Miriam Parry, Prashanth Reddy, Robin Fackrell, Kallol Ray Chaudhuri
Abstract In the UK, guidance exists to aid clinicians and patients deciding when treatment for Parkinson’s disease (PD) should be initiated and which therapies to consider. National Institute for Health and Care Excellence (NICE) guidance recommends that before starting PD treatment clinicians should discuss the following: the patient’s individual clinical circumstances; lifestyle; preferences; needs
-
Characterization of Novel Human β-glucocerebrosidase Antibodies for Parkinson’s Disease Research J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-01-23 Tiffany Jong, Alexandra Gehrlein, Ellen Sidransky, Ravi Jagasia, Yu Chen
Abstract Background: Mutations in GBA1, which encodes the lysosome enzyme β-glucocerebrosidase (also referred to as acid β-glucosidase or GCase), are the most common genetic risk factor for Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Evidence also suggests that loss of GCase activity is implicated in PD without GBA1 mutations. Consequently, therapies targeting GCase are actively being
-
Chronotropic Incompetence During Exercise Testing as a Marker of Autonomic Dysfunction in Individuals with Early Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-01-23 Garett Griffith, Guillaume Lamotte, Niyati Mehta, Peng Fan, Juliana Nikolich, Victoria Springman, Erin Suttman, Elizabeth Joslin, Katherine Balfany, MacKenzie Dunlap, Wendy M. Kohrt, Cory L. Christiansen, Edward L. Melanson, Deborah Josbeno, Lana M. Chahine, Charity G. Patterson, Daniel M. Corcos
Abstract Background: An attenuated heart rate response to exercise, termed chronotropic incompetence, has been reported in Parkinson’s disease (PD). Chronotropic incompetence may be a marker of autonomic dysfunction and a cause of exercise intolerance in early stages of PD. Objective: To investigate the relationship between chronotropic incompetence, orthostatic blood pressure change (supine – standing)
-
Working Memory Training Responsiveness in Parkinson’s Disease Is Not Determined by Cortical Thickness or White Matter Lesions J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-01-22 Kathrin Giehl, Hendrik Theis, Anja Ophey, Jochen Hammes, Paul Reker, Carsten Eggers, Gereon R. Fink, Elke Kalbe, Thilo van Eimeren
Abstract Patients with Parkinson’s disease are highly vulnerable for cognitive decline. Thus, early intervention by means of working memory training (WMT) may be effective for the preservation of cognition. However, the influence of structural brain properties, i.e., cortical thickness and volume of white matter lesions on training responsiveness have not been studied. Here, behavioral and neuroimaging
-
Action Observation and Motor Imagery as a Treatment in Patients with Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-01-13 Susanna Mezzarobba, Gaia Bonassi, Laura Avanzino, Elisa Pelosin
Abstract Action observation (AO) and motor imagery (MI) has emerged as promising tool for physiotherapy intervention in Parkinson’s disease (PD). This narrative review summarizes why, how, and when applying AO and MI training in individual with PD. We report the neural underpinning of AO and MI and their effects on motor learning. We examine the characteristics and the current evidence regarding the
-
The Role of Diet in Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-01-13 Kira N. Tosefsky, Julie Zhu, Yolanda N. Wang, Joyce S.T. Lam, Amanda Cammalleri, Silke Appel-Cresswell
Abstract The aim of this review is to examine the intersection of Parkinson’s disease (PD) with nutrition, to identify best nutritional practices based on current evidence, and to identify gaps in the evidence and suggest future directions. Epidemiological work has linked various dietary patterns and food groups to changes in PD risk; however, fewer studies have evaluated the role of various diets
-
A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-01-13 Milton H. Werner, C. Warren Olanow, Andrew McGarry, Christopher Meyer, Sydney Kruger, Carl Klint, Jacqueline Pellecchia, Shannon Walaker, Larry Ereshefsky, Lawrence Blob, Howard Hassman, Carlos Rodriguez, Emil Samara, Beth Safirstein, Aaron Ellenbogen
Abstract Background: Pre-clinical studies suggest that c-Abl activation may play an important role in the etiology of Parkinson’s disease, making c-Abl an important target to evaluate for potential disease-modification. Objective: To assess safety, tolerability, and pharmacokinetics of the c-Abl inhibitor risvodetinib (IkT-148009) in healthy subjects and participants with Parkinson’s disease. Methods:
-
The Importance of Digital Health Literacy in an Evolving Parkinson’s Disease Care System J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-01-13 Christine D. Esper, Blanca Y. Valdovinos, Ruth B. Schneider
Abstract Digital health technologies are growing at a rapid pace and changing the healthcare landscape. Our current understanding of digital health literacy in Parkinson’s disease (PD) is limited. In this review, we discuss the potential challenges of low digital health literacy in PD with particular attention to telehealth, deep brain stimulation, wearable sensors, and smartphone applications. We
-
Another Step Forward for Freezing of Gait in Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-01-11 Anton Fomenko, Alfonso Fasano, Suneil K. Kalia
Abstract The study “A spinal cord neuroprosthesis for locomotor deficits due to Parkinson’s disease” by Milekovic et al. introduces a novel neuroprosthesis for treating locomotor deficits in late-stage Parkinson’s disease (PD). This approach employs an epidural spinal array targeting dorsal roots and electromyography to create a spatiotemporal map of muscle activation, aiming to restore natural gait
-
Non-Motor Symptom Management: Insights into Adherence to Treatment Guidelines in Parkinson’s Disease Patients J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-01-11 Carin Janz, Jonathan Timpka, Kristina Rosqvist, Gesine Paul, Alexander Storch, Per Odin
Abstract Background: Non-motor symptoms (NMS) reduce quality of life in Parkinson’s disease (PD) patients, who experience three times more NMS than individuals without PD. While there are international and national NMS treatment guidelines, their implication in clinical practice remains unclear. Objective: This study aimed to investigate the adherence to pharmacological NMS treatment guidelines in
-
Parkinson’s Disease Is Predominantly an Environmental Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2024-01-09 E. Ray Dorsey, Bastiaan R. Bloem
Abstract Parkinson’s disease is the world’s fastest growing brain disorder, and exposure to environmental toxicants is the principal reason. In this paper, we consider alternative, but unsatisfactory, explanations for its rise, including improved diagnostic skills, aging populations, and genetic causes. We then detail three environmental toxicants that are likely among the main causes of Parkinson’s
-
Advice to People with Parkinson’s in My Clinic: Exercise J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-12-30 Daniel M. Corcos, Guillaume Lamotte, Nijee S. Luthra, Kathleen E. McKee
Abstract There is compelling evidence that exercise must be part of main line therapy for people with Parkinson’s disease. In this viewpoint, we outline the four key components of exercise: aerobic exercise, resistance exercise, flexibility exercise, and neuromotor exercises (posture, gait, balance, and agility) that can improve both motor and non-motor symptoms of the disease and, in the case of aerobic
-
The Use of Image Guided Programming to Improve Deep Brain Stimulation Workflows with Directional Leads in Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-12-30 Anne-Sophie Rolland, Gustavo Touzet, Nicolas Carriere, Eugenie Mutez, Alexandre Kreisler, Clemence Simonin, Gregory Kuchcinski, Najib Chalhoub, Jean-Pierre Pruvo, Luc Defebvre, Nicolas Reyns, David Devos, Caroline Moreau
Abstract Background: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a preferred treatment for parkinsonian patients with severe motor fluctuations. Proper targeting of the STN sensorimotor segment appears to be a crucial factor for success of the procedure. The recent introduction of directional leads theoretically increases stimulation specificity in this challenging area but also
-
Alpha-Synuclein Pre-Formed Fibrils Injected into Prefrontal Cortex Primarily Spread to Cortical and Subcortical Structures J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-12-30 Matthew A. Weber, Gemma Kerr, Ramasamy Thangavel, Mackenzie M. Conlon, Serena B. Gumusoglu, Kalpana Gupta, Hisham A. Abdelmotilib, Oday Halhouli, Qiang Zhang, Joel C. Geerling, Nandakumar S. Narayanan, Georgina M. Aldridge
Abstract Background: Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) are characterized by diffuse spread of alpha-synuclein (α-syn) throughout the brain. Patients with PDD and DLB have a neuropsychological pattern of deficits that include executive dysfunction, such as abnormalities in planning, timing, working memory, and behavioral flexibility. The prefrontal cortex (PFC) plays
-
Concept Mapping to Define Components for an Occupation-Based Intervention for Parkinson’s Disease and Anxiety J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-12-27 Christopher J. Lovegrove, Ingrid H.W.M. Sturkenboom, Jonathan Marsden, Katrina Bannigan
Abstract Background: Anxiety, a common symptom of Parkinson’s disease (PD), results in reduced life quality, reduced participation in meaningful roles and daily activities, and increased health burden. There are no evidence-based interventions to reduce the impact of anxiety in PD on participation. Objective: This study aimed to identify the key components required for the co-production of an occupation-
-
Machine Learning-Based Classification of Parkinson’s Disease Patients Using Speech Biomarkers J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-12-29 Mohammad Amran Hossain, Francesco Amenta
Abstract Background: Parkinson’s disease (PD) is the most prevalent neurodegenerative movement disorder and a growing health concern in demographically aging societies. The prevalence of PD among individuals over the age of 60 and 80 years has been reported to range between 1% and 4% . A timely diagnosis of PD is desirable, even though it poses challenges to medical systems. Objective: This study aimed
-
Prevalence of Concomitant Pathologies in Parkinson’s Disease: Implications for Prognosis, Diagnosis, and Insights into Common Pathogenic Mechanisms J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-12-18 Lauren Walker, Johannes Attems
Abstract Pathologies characteristic of Alzheimer’s disease (i.e., hyperphosphorylated tau and amyloid-β (Aβ) plaques), cardiovascular disease, and limbic predominant TDP-43 encephalopathy (LATE) often co-exist in patients with Parkinson’s disease (PD), in addition to Lewy body pathology (α-synuclein). Numerous studies point to a putative synergistic relationship between hyperphosphorylation tau, Aβ
-
Delivery of Allied Health Therapies to People with Parkinson’s Disease in Africa J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-12-16 Roberto Cilia, Marieke C.J. Dekker, Esther Cubo, Mary W. Agoriwo
Abstract Allied health therapies refer to a range of healthcare professionals, including physiotherapists, occupational and speech-language therapists, who aim to optimize daily function and quality of life in conjunction with medical care. In this narrative review of literature on allied health therapies in people with Parkinson’s disease (PD), we focused on the diversity in healthcare access, state
-
Understanding the Role of CDH4 in Multiple System Atrophy Brain J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-12-19 Finula I. Isik, Jared S. Katzeff, YuHong Fu, Woojin Scott Kim
Abstract Background: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disease clinically characterized by parkinsonism, cerebellar ataxia, and autonomic dysfunction. A major pathological feature of MSA is the presence of α-synuclein aggregates in oligodendrocytes, the myelinating cells of the central nervous system. A genome-wide association study revealed that the CDH4 gene
-
Orthostatic Hypotension in Multiple System Atrophy: Related Factors and Disease Prognosis J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-12-19 Qirui Jiang, Lingyu Zhang, Junyu Lin, Qianqian Wei, Chunyu Li, Yanbing Hou, Ruwei Ou, Kuncheng Liu, Tianmi Yang, Yi Xiao, Bi Zhao, Ying Wu, Huifang Shang
Abstract Background: Multiple system atrophy (MSA) is a rare neurodegenerative disease characterized by Parkinsonism, ataxia, and autonomic nervous failure. Orthostatic hypotension (OH) is the main feature of central vascular autonomic failure in MSA. Objective: The study aimed elucidate the effects of OH on cognitive function, disease milestones, and survival. Methods: A total of 444 patients with
-
The ‘Pants-Sign’: A Predictor for Falling in People with Parkinson’s Disease? J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-12-13 Jamie A.F. Jansen, Anouk Tosserams, Vivian G.M. Weerdesteyn, Bastiaan R. Bloem, Jorik Nonnekes
Abstract Background: A history of falls is the most established predictor of future falls in people with Parkinson’s disease (PD). However, predicting a first fall remains challenging. Objective: To assess whether experiencing difficulties putting on pants while standing is a viable predictor of future falling, and specifically a first fall, in persons with PD. We define this ‘Pants-sign’ as people
-
Remote Delivery of Allied Health Therapies in Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-11-22 Ryan P. Duncan, Gammon M. Earhart
Abstract Remote delivery of allied health therapies has long been possible, but adoption has been limited in some disciplines until relatively recently. The COVID-19 pandemic drove dramatic increases in use of remote delivery within allied health. This review summarizes the latest evidence on remotely-delivered physical therapy, occupational therapy, and speech therapy and discusses associated challenges
-
Astrocytes and Alpha-Synuclein: Friend or Foe? J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-11-18 Hakan Ozoran, Rahul Srinivasan
Abstract Despite its devastating disease burden and alarming prevalence, the etiology of Parkinson’s disease (PD) remains to be completely elucidated. PD is characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta and this correlates with the accumulation of misfolded α-synuclein. While the aggregation of α-synuclein in the form of Lewy bodies or Lewy neurites
-
An International Multi-Stakeholder Delphi Survey Study on the Design of Disease Modifying Parkinson’s Disease Trials J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-11-18 Marie-Louise Zeissler, Kevin McFarthing, Karen G. Raphael, Gary Rafaloff, Richard Windle, Camille B. Carroll
Abstract Background: Design of disease modification (DM) trials for Parkinson’s disease (PD) is challenging. Successful delivery requires a shared understanding of priorities and practicalities. Objective: To seek stakeholder consensus on phase 3 trials’ overall goals and structure, inclusion criteria, outcome measures, and trial delivery and understand where perspectives differ. Methods: An international
-
The Etiology of Parkinson’s Disease: New Perspectives from Gene-Environment Interactions J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-11-17 Jolien S. Bogers, Bastiaan R. Bloem, Jonas M. Den Heijer
Abstract Parkinson’s disease is now the most rapidly growing neurodegenerative disease worldwide. It is therefore critical to identify which factors, and to what extent, contribute to the multifactorial etiology of Parkinson’s disease. Here, we address two interesting elements from the perspective of genetics, namely (a) the estimated age of several genetic risk factors related to Parkinson’s disease;
-
Association Between Menopausal Hormone Therapy and Risk for Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-11-17 Jin-Sung Yuk, Seong Ho Jeong
Abstract Background: The relationship between menopausal hormone therapy (MHT) and risk of Parkinson’s disease (PD) remains controversial. Objective: This nationwide population-based cohort study investigated the association between MHT and PD development. Methods: Data from the National Health Insurance System of South Korea from 2007 to 2020 were used. The MHT group included women who underwent MHT
-
Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson’s Disease: An Open-Label, Randomized, Crossover Study J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-11-16 Fabrizio Stocchi, Olivier Rascol, Werner Poewe, K. Ray Chaudhuri, Jan Kassubek, Lydia Lopez Manzanares, Yi Zhang, Alyssa Bowling, Eric Pappert, Stacy Wu
Abstract Background: Apomorphine sublingual film (SL-APO) and subcutaneous apomorphine (SC-APO) have been used for the treatment of OFF episodes in Parkinson’s disease (PD). No study has prospectively compared efficacy and safety of these formulations. Objective: To compare SL-APO with SC-APO for treatment of OFF episodes in PD. Methods: An open-label, randomized, crossover study assessed SL-APO versus
-
Pesticides and the Microbiome-Gut-Brain Axis: Convergent Pathways in the Pathogenesis of Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-11-03 Kristina Kulcsarova, Corinna Bang, Daniela Berg, Eva Schaeffer
Abstract The increasing global burden of Parkinson’s disease (PD), termed the PD pandemic, is exceeding expectations related purely to population aging and is likely driven in part by lifestyle changes and environmental factors. Pesticides are well recognized risk factors for PD, supported by both epidemiological and experimental evidence, with multiple detrimental effects beyond dopaminergic neuron
-
Is There an Association Between Parkinson’s Disease and Periodontitis? A Systematic Review and Meta-Analysis J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-11-03 Yiqun Chen, Yining Jin, Kun Li, Haojie Qiu, Zihan Jiang, Jinrong Zhu, Siqi Chen, Wei Xie, Guangyong Chen, Dehao Yang
Abstract Background: Multiple observational studies have yielded controversial results regarding the association between Parkinson’s disease (PD) and periodontitis. Objective: This systematic review and meta-analysis was conducted to ascertain their bidirectional relationship. Methods: A literature search for relevant studies was performed in PubMed, EMBASE, the Cochrane Library, and Web of Science
-
Comprehensive Evaluation of Psychotic Features and Their Clinical Correlates in Early Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-10-09 Ioanna Pachi, Vassilis Papadopoulos, Christos Koros, Athina Maria Simitsi, Anastasia Bougea, Maria Bozi, Nikos Papagiannakis, Rigas Filippos Soldatos, Dimitra Kolovou, George Pantes, Nikolaos Scarmeas, Georgios Paraskevas, Konstantinos Voumvourakis, Sokratis G. Papageorgiou, Konstantinos Kollias, Nikos Stefanis, Leonidas Stefanis
Abstract Background: Some reports suggest that psychotic features may occur in the early stages of Parkinson’s disease (PD), but sensitive tools have not been utilized. Objective: The aim was to evaluate the presence of psychotic symptoms using detailed scales and to assess the association with clinical characteristics. Methods: Healthy controls and patients within three years of PD onset were recruited
-
Feasibility and Proof-of-Concept of Delivering an Autonomous Music-Based Digital Walking Intervention to Persons with Parkinson’s Disease in a Naturalistic Setting J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-10-11 Jenna A. Zajac, Franchino Porciuncula, James T. Cavanaugh, Colin McGregor, Brian A. Harris, Kirsten E. Smayda, Louis N. Awad, Alexander Pantelyat, Terry D. Ellis
Abstract Background: Reduced motor automaticity in Parkinson’s disease (PD) negatively impacts the quality, intensity, and amount of daily walking. Rhythmic auditory stimulation (RAS), a clinical intervention shown to improve walking outcomes, has been limited by barriers associated with the need for ongoing clinician input. Objective: To assess the feasibility, proof-of-concept, and preliminary clinical
-
Overnight Distribution of REM Sleep Features in People with Parkinson’s Disease (PD) and Non-PD Controls J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-09-30 Andrew Dagay, Shani Oz, Shlomit Katzav, Danielle Wasserman, Riva Tauman, Avner Thaler, Nir Giladi, Anat Mirelman
Abstract Background: Rapid eye movement (REM) sleep behavior disorder (RBD) is a leading predictor of Parkinson’s disease (PD). Diagnosis is performed in the sleep laboratory by detecting pathological REM sleep without atonia (RSWA). The evidence on the overnight distribution of RSWA% is conflicting. Objective: To investigate the temporal distribution of the number of ocular movements per REM sleep
-
Reading Difficulties in Parkinson’s Disease: A Stepped Care Model for Neurovisual Rehabilitation J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-09-28 Iris van der Lijn, Gera A. de Haan, Fleur E. van der Feen, Anne C.L. Vrijling, Catharina Stellingwerf, Anselm B.M. Fuermaier, Pia Langenberg, Teus van Laar, Joost Heutink
Abstract Background: People with Parkinson’s disease (PD) frequently experience reading difficulties. Little is known about what functional impairments distinguish people with PD with and without reading difficulties and how these should guide rehabilitation. Objective: To provide concrete advice for an efficient stepped care model for reading difficulties in PD, based on extensive functional assessments
-
Sleep Disorders in Early-Onset Parkinsonism: A Population-Based Study J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-09-20 Stuart J. McCarter, Emanuele Camerucci, Aidan F. Mullan, Cole D. Stang, Pierpaolo Turcano, Erik K. St. Louis, Bradley F. Boeve, Rodolfo Savica
Abstract Background: Sleep disturbances are common in parkinsonian disorders; however, whether sleep disorders affect individuals with early-onset parkinsonism and whether they differ from individuals with typical-onset parkinsonism is unknown. Objective: To compare the prevalence and incidence of sleep disorders before and after parkinsonian motor symptom onset between individuals with early onset
-
Burden of Parkinsonism and Parkinson’s Disease on Health Service Use and Outcomes in Latin America J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-09-16 Dani J. Kim, Ana M. Rodriguez-Salgado, Juan J. Llibre-Rodriguez, Isaac Acosta, Ana Luisa Sosa, Daisy Acosta, Ivonne Z. Jimenez-Velasquez, Mariella Guerra, Aquiles Salas, Christine Jeyachandran, Ricardo López-Contreras, Heike Hesse, Caroline Tanner, Jorge J. Llibre-Guerra, Matthew Prina
Abstract Background: Little is known about the burden of parkinsonism and Parkinson’s disease (PD) in Latin America. Better understanding of health service use and clinical outcomes in PD is needed to improve its prognosis. Objective: The aim of the study was to estimate the burden of parkinsonism and PD in six Latin American countries. Methods: 12,865 participants aged 65 years and older from the
-
Cerebral Small Vessel Disease Is Associated with Motor, Cognitive, and Emotional Dysfunction in Multiple System Atrophy J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-09-16 Xiao-Li Yang, Yu Guo, Shu-Fen Chen, Mei Cui, Rong-Rong Shao, Yu-Yuan Huang, Yu-Fan Luo, Zhi-Yuan Dong, Qiang Dong, Dan-Hong Wu, Jin-Tai Yu
Abstract Background: Cerebral small vessel disease (CSVD) has not been systematically studied in patients with multiple system atrophy (MSA). Objective: We sought to explore whether MSA patients suffer from a heavier CSVD burden relative to healthy individuals and whether CSVD has a relationship with motor, cognitive, and emotional dysfunction in patients with MSA. Methods: This study consecutively
-
Parkinson’s Pals: A Student-Led Program to Facilitate Intergenerational Connections and Promote Psychosocial Well-Being Among Persons with Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-09-19 Udit Garg, Jaskeerat Gujral, Om H. Gandhi, Nabila Dahodwala, Linda Joy Goldner, Sara Hughes, Suzanne Reichwein, Lauren Zelouf, Whitley W. Aamodt
Abstract Parkinson’s disease (PD) causes unique motor and non-motor symptoms. Despite symptomatic treatment with pharmacotherapies, many persons with PD report feelings of loneliness and demoralization as their disease progresses. These symptoms greatly interfere with quality of life, necessitating novel treatment strategies. In this report, we introduce a new student-led program to improve psychosocial
-
Incretin Mimetics Restore the ER-Mitochondrial Axis and Switch Cell Fate Towards Survival in LUHMES Dopaminergic-Like Neurons: Implications for Novel Therapeutic Strategies in Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-09-14 Theodora Panagaki, Elisa B. Randi, Csaba Szabo, Christian Hölscher
Abstract Background: Parkinson’s disease (PD) is a progressive neurodegenerative movement disorder that afflicts more than 10 million people worldwide. Available therapeutic interventions do not stop disease progression. The etiopathogenesis of PD includes unbalanced calcium dynamics and chronic dysfunction of the axis of the endoplasmic reticulum (ER) and mitochondria that all can gradually favor
-
Non-Pharmacological Treatment of Autonomic Dysfunction in Parkinson’s Disease and Other Synucleinopathies J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-09-07 Jose-Alberto Palma, Roland D. Thijs
Abstract Symptoms of autonomic dysfunction are prevalent and can be very debilitating, reducing the quality of life in patients with Parkinson’s disease (PD) and other synucleinopathies such as dementia with Lewy bodies and multiple system atrophy. Non-pharmacological therapies are key to effective management and are frequently used alone in patients with mild autonomic symptoms, or in combination
-
Distinct Patterns of Gene Expression Changes in the Colon and Striatum of Young Mice Overexpressing Alpha-Synuclein Support Parkinson’s Disease as a Multi-System Process J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-08-19 Elizabeth J. Videlock, Asa Hatami, Chunni Zhu, Riki Kawaguchi, Han Chen, Tasnin Khan, Ashwaq Hamid Salem Yehya, Linsey Stiles, Swapna Joshi, Jill M. Hoffman, Ka Man Law, Carl Robert Rankin, Lin Chang, Nigel T. Maidment, Varghese John, Daniel H. Geschwind, Charalabos Pothoulakis
Abstract Background: Evidence supports a role for the gut-brain axis in Parkinson’s disease (PD). Mice overexpressing human wild type α– synuclein (Thy1-haSyn) exhibit slow colonic transit prior to motor deficits, mirroring prodromal constipation in PD. Identifying molecular changes in the gut could provide both biomarkers for early diagnosis and gut-targeted therapies to prevent progression. Objective:
-
Exploring the Complex Phenotypes of Impaired Finger Dexterity in Mild-to-moderate Stage Parkinson’s Disease: A Time-Series Analysis J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-08-12 Pattamon Panyakaew, Kotchakorn Duangjino, Apiwoot Kerddonfag, Teerit Ploensin, Krerk Piromsopa, Chanon Kongkamol, Roongroj Bhidayasiri
Abstract Background: Impaired dexterity is an early motor symptom in Parkinson’s disease (PD) that significantly impacts the daily activity of patients; however, what constitutes complex dexterous movements remains controversial. Objective: To explore the characteristics of finger dexterity in mild-to-moderate stage PD. Methods: We quantitatively assessed finger dexterity in 48 mild-to-moderate stage
-
Outcome Measures for Disease-Modifying Trials in Parkinson’s Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-07-31 Cristina Gonzalez-Robles, Rimona S. Weil, Daniel van Wamelen, Michèle Bartlett, Matthew Burnell, Caroline S. Clarke, Michele T. Hu, Brook Huxford, Ashwani Jha, Christian Lambert, Michael Lawton, Georgia Mills, Alastair Noyce, Paola Piccini, Kuhan Pushparatnam, Lynn Rochester, Carroll Siu, Caroline H. Williams-Gray, Marie-Louise Zeissler, Henrik Zetterberg, Camille B. Carroll, Thomas Foltynie, Anette
Abstract Background: Multi-arm, multi-stage (MAMS) platform trials can accelerate the identification of disease-modifying treatments for Parkinson’s disease (PD) but there is no current consensus on the optimal outcome measures (OM) for this approach. Objective: To provide an up-to-date inventory of OM for disease-modifying PD trials, and a framework for future selection of OM for such trials. Methods:
-
Can Digital Mobility Assessment Enhance the Clinical Assessment of Disease Severity in Parkinson’s Disease? J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-07-31 Cameron Kirk, Rana Zia Ur Rehman, Brook Galna, Lisa Alcock, Saverio Ranciati, Luca Palmerini, Judith Garcia-Aymerich, Clint Hansen, Eva Schaeffer, Daniela Berg, Walter Maetzler, Lynn Rochester, Silvia Del Din, Alison J. Yarnall
Abstract Background: Real-world walking speed (RWS) measured using wearable devices has the potential to complement the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS III) for motor assessment in Parkinson’s disease (PD). Objective: Explore cross-sectional and longitudinal differences in RWS between PD and older adults (OAs), and whether RWS was related to motor disease
-
40-Year Incidence of Early-Onset Parkinson’s Disease in Southeast Minnesota J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-07-26 Emanuele Camerucci, Aidan F. Mullan, Pierpaolo Turcano, James Bower, Capucine Piat, J.E. Ahlskog, Rodolfo Savica
Abstract Background: Parkinson’s disease (PD) most commonly surfaces at middle age. An earlier onset is named early-onset Parkinson’s disease (EOPD), but the exact definition is a matter of ongoing scientific debate. Objective: To investigate 40-year EOPD incidence trends in a population-based cohort of parkinsonism in Olmsted County, Minnesota. Methods: We used the Rochester Epidemiology Project (REP)
-
Predicting the Prognosis of Multiple System Atrophy Using Cluster and Principal Component Analysis J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-07-26 Juanjuan Du, Shishuang Cui, Pei Huang, Chao Gao, Pingchen Zhang, Jin Liu, Hongxia Li, Maoxin Huang, Xin Shen, Zixian Liu, Zilu Chen, Yuyan Tan, Shengdi Chen
Abstract Background: Multiple system atrophy (MSA) is an intractable neurodegenerative disorder with poorly understanding of prognostic factors. Objective: The purpose of this retrospective longitudinal study was to explore the main predictors of survival of MSA patients with new clinical subtypes based on cluster analysis. Methods: A total of 153 Chinese MSA patients were recruited in our study. The
-
May Bradykinesia Features Aid in Distinguishing Parkinson’s Disease, Essential Tremor, And Healthy Elderly Individuals? J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-07-27 Giulia Paparella, Antonio Cannavacciuolo, Luca Angelini, Davide Costa, Daniele Birreci, Danilo Alunni Fegatelli, Andrea Guerra, Alfredo Berardelli, Matteo Bologna
Abstract Background: Bradykinesia is the hallmark feature of Parkinson’s disease (PD); however, it can manifest in other conditions, including essential tremor (ET), and in healthy elderly individuals. Objective: Here we assessed whether bradykinesia features aid in distinguishing PD, ET, and healthy elderly individuals. Methods: We conducted simultaneous video and kinematic recordings of finger tapping
-
The Effects of Subthalamic Nucleus Deep Brain Stimulation and Retention Delay on Memory-Guided Reaching Performance in People with Parkinson’s Disease J. Parkinson’s Dis. (IF 5.2) Pub Date : 2023-07-27 Michael P. Trevarrow, Miranda J. Munoz, Yessenia M. Rivera, Rishabh Arora, Quentin H. Drane, Joshua M. Rosenow, Sepehr B. Sani, Gian D. Pal, Leonard Verhagen Metman, Lisa C. Goelz, Daniel M. Corcos, Fabian J. David
Abstract Background: Subthalamic nucleus deep brain stimulation (STN-DBS) improves intensive aspects of movement (velocity) in people with Parkinson’s disease (PD) but impairs the more cognitively demanding coordinative aspects of movement (error). We extended these findings by evaluating STN-DBS induced changes in intensive and coordinative aspects of movement during a memory-guided reaching task